By Elias Schisgall
Shares of Harrow rose after the company reaffirmed its full-year guidance for revenue between $270 million and $280 million.
Shares were trading up 6.9% to $43.76 Monday morning The stock has gained 47% in the past year.
The ophthalmic disease management company said Monday that its confidence in the outlook was based on execution across its programs.
Harrow said it was looking to double the Veyve sales force to 100 by Memorial Day and double the surgical-based sales force for Triesence. The company is also looking to expand Iheezo into the office-based setting, which it said is expected to accelerate demand.
The company said Monday that Patrick Sullivan, who joined Harrow as head of commercial in August, was promoted to chief commercial officer.
Following the September acquisition of Melt Pharmaceuticals, Harrow said that it remains on track to file a New Drug Application for Melt-300 in the first half of 2027.
Harrow also said that its ImprimisRx business was voluntarily leaving the California market after paying a $157,000 fine to the California Board of Pharmacy, citing the state's "increasingly unpredictable, costly, and punitive regulatory environment." It said the exit from California was not financially material to Harrow.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
February 02, 2026 10:07 ET (15:07 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.